ERBB2 and ovarian carcinoma: Even though the therapeutic relevance of these findings in PTs is currently unknown, clinical evidence supports the role of the majority of these mutations as predictors of response to specific therapeutic agents in other malignancies.27–31 In fact, AZD5363, an AKT inhibitor has been shown to have therapeutic activity in breast and ovarian cancer harboring the AKT1 E17K mutation,27 and neratinib, an irreversible dual ERBB2/EGFR tyrosine kinase inhibitor, has been found to be active in breast cancers with activating ERBB2 mutations.28